27638250|t|Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection
27638250|a|The number of kidney transplant recipients (KTRs) after nonrenal solid organ transplantation (SOT) has increased to almost 5%. Knowledge on patient and allograft outcomes, infections, and alloreactivity, however, remains scarce. We studied 40 KTRs after nonrenal SOT. Seven hundred and twenty primary KTRs and 119 repeat KTRs were used for comparison. Samples were collected pretransplantation, at +1, +2, and +3 months post-transplantation. Alloreactive and CMV-specific T cells were measured by interferon-γ ELISPOT assay. Patient survival in KTRs after SOT, primary and repeat KTRs was comparable. While death -censored allograft survival was comparable between KTRs after SOT and primary KTRs, KTRs after SOT showed superior 5-year death -censored allograft survival of 92.5% compared to 81.2% in repeat KTRs. Interestingly, KTRs after SOT show less preformed panel-reactive antibodies, frequencies of alloreactive T cells, and acute rejections compared to repeat KTRs. KTRs after SOT, however, show higher incidences of EBV viremia and PTLD, sepsis, and death from sepsis. Impaired CMV-specific cellular immunity was associated with more CMV replication compared to repeat KTRs. Our results suggest comparable patient and allograft outcomes in KTRs after SOT and primary KTRs. The observed low alloreactivity may contribute to excellent allograft outcomes. Caution should be taken in KTRs after SOT regarding infectious complications due to overimmunosuppression.
27638250	0	28	Kidney transplant recipients	T033	C4304779
27638250	35	71	nonrenal solid organ transplantation	T061	C0029216
27638250	81	95	alloreactivity	T039	C0301873
27638250	113	117	risk	T078	C0035647
27638250	121	130	infection	T046	C3714514
27638250	145	173	kidney transplant recipients	T033	C4304779
27638250	175	179	KTRs	T033	C4304779
27638250	187	223	nonrenal solid organ transplantation	T061	C0029216
27638250	225	228	SOT	T061	C0029216
27638250	271	278	patient	T101	C0030705
27638250	283	292	allograft	T061	C0040739
27638250	293	301	outcomes	T080	C0085415
27638250	303	313	infections	T046	C3714514
27638250	319	333	alloreactivity	T039	C0301873
27638250	363	370	studied	T062	C2603343
27638250	374	378	KTRs	T033	C4304779
27638250	385	397	nonrenal SOT	T061	C0029216
27638250	432	436	KTRs	T033	C4304779
27638250	452	456	KTRs	T033	C4304779
27638250	483	490	Samples	T031	C0504082
27638250	506	524	pretransplantation	T079	C1254367
27638250	551	571	post-transplantation	T079	C1254367
27638250	573	585	Alloreactive	T039	C0301873
27638250	590	602	CMV-specific	T005	C0010825
27638250	603	610	T cells	T025	C0039194
27638250	628	654	interferon-γ ELISPOT assay	T059	C0920508
27638250	656	663	Patient	T101	C0030705
27638250	664	672	survival	T052	C0038952
27638250	676	680	KTRs	T033	C4304779
27638250	687	690	SOT	T061	C0029216
27638250	711	715	KTRs	T033	C4304779
27638250	738	743	death	T040	C0011065
27638250	754	763	allograft	T061	C0040739
27638250	764	772	survival	T052	C0038952
27638250	796	800	KTRs	T033	C4304779
27638250	807	810	SOT	T061	C0029216
27638250	823	827	KTRs	T033	C4304779
27638250	829	833	KTRs	T033	C4304779
27638250	840	843	SOT	T061	C0029216
27638250	860	866	5-year	T079	C0439234
27638250	867	872	death	T040	C0011065
27638250	883	892	allograft	T061	C0040739
27638250	893	901	survival	T052	C0038952
27638250	939	943	KTRs	T033	C4304779
27638250	960	964	KTRs	T033	C4304779
27638250	971	974	SOT	T061	C0029216
27638250	995	1020	panel-reactive antibodies	T059	C1141951
27638250	1022	1033	frequencies	T079	C0439603
27638250	1037	1049	alloreactive	T039	C0301873
27638250	1050	1057	T cells	T025	C0039194
27638250	1063	1079	acute rejections	T033	C3273245
27638250	1099	1103	KTRs	T033	C4304779
27638250	1105	1109	KTRs	T033	C4304779
27638250	1116	1119	SOT	T061	C0029216
27638250	1142	1152	incidences	T081	C0021149
27638250	1156	1167	EBV viremia	T047	C1701919
27638250	1172	1176	PTLD	T191	C0432487
27638250	1178	1184	sepsis	T047	C0243026
27638250	1190	1195	death	T040	C0011065
27638250	1201	1207	sepsis	T047	C0243026
27638250	1218	1230	CMV-specific	T005	C0010825
27638250	1231	1248	cellular immunity	T040	C0020966
27638250	1253	1268	associated with	T080	C0332281
27638250	1274	1277	CMV	T005	C0010825
27638250	1278	1289	replication	T043	C0042774
27638250	1309	1313	KTRs	T033	C4304779
27638250	1346	1353	patient	T101	C0030705
27638250	1358	1367	allograft	T061	C0040739
27638250	1368	1376	outcomes	T080	C0085415
27638250	1380	1384	KTRs	T033	C4304779
27638250	1391	1394	SOT	T061	C0029216
27638250	1407	1411	KTRs	T033	C4304779
27638250	1430	1444	alloreactivity	T039	C0301873
27638250	1473	1482	allograft	T061	C0040739
27638250	1483	1491	outcomes	T080	C0085415
27638250	1520	1524	KTRs	T033	C4304779
27638250	1531	1534	SOT	T061	C0029216
27638250	1545	1569	infectious complications	T047	C0940933
27638250	1577	1598	overimmunosuppression	T047	C4048329